News & enforcement.
The regulatory actions, lawsuits, and industry shifts moving the research-peptide market. Every item links to its source and is tagged by how much weight it deserves — a primary FDA or court document is not the same as a forum rumor, and we mark which is which.
- Official record2026-08-05· FDA MedWatch
Victory Medical Center Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levels
FOR IMMEDIATE RELEASE – August 5, 2026 – Austin, Texas, Victory Medical Center Pharmacy is voluntarily recalling certain lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials to the patient level. The product is being recalled because pharmacy testing identified elevated bacterial endotoxin leve
Primary government, court, or regulatory documentsource - News2026-06-01· KFF Health News
Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight
Investigation into the grey-market/telehealth GLP-1 boom: medication-error reports involving GLP-1s rose from ~2,000 (2020) to more than 25,000 (2025), and poison-control overdose calls jumped nearly 1,500% since 2019, with several patient-harm case studies from compounded prescriptions.
Reported by an established news outletsource - Industry blog2026-03-06· Industry trackers (TitrateLab 'Peptide Vendor Graveyard')
Peptide Sciences shuts down — largest U.S. grey-market peptide vendor exits
Peptide Sciences, described by industry trackers as the largest U.S. grey-market peptide vendor, announced a voluntary shutdown. Reported by industry retrospectives rather than mainstream news; exact date and framing are as claimed by those trackers and unverified independently.
Industry tracker/blog — not independently verifiedsource - Industry blog2026-01-27· Industry trackers (TitrateLab, The Peptide Catalog)
Science.bio announces voluntary closure
Research-chemical vendor Science.bio announced a voluntary wind-down, committing to refunds or order fulfillment; commentators framed it as a signal of a broader retreat from the grey market amid enforcement pressure. Reported by industry blogs/trackers, not mainstream news.
Industry tracker/blog — not independently verifiedsource - Official record2025-12-10· U.S. Department of Justice, USAO Northern District of Indianaparadigm-peptides
United States v. Matthew Kawa et al. — Paradigm Peptides guilty plea
Matthew Kawa and Jennifer Stechkober pleaded guilty over the operation of Paradigm Peptides, which sold SARMs, hCG and peptides nationwide; federal investigators found products labeled as SARMs actually contained testosterone (a Schedule III controlled substance) and that the peptide/hCG products were unapproved new drugs. Kawa also owned Amino Asylum.
Primary government, court, or regulatory documentsource - News2025-09-19· STAT News
FDA takes on GLP-1 compounding boom with warnings about misleading marketing
The FDA issued more than 50 warning letters to telehealth companies, concierge practices, and medical spas selling compounded semaglutide/tirzepatide, focused on false claims that the compounded drugs are equivalent to FDA-approved medicines.
Reported by an established news outletsource - Industry blog2025-08-01· PeptideExaminer
The FDA's War on Peptides: A 2024–2026 Enforcement Timeline
Industry-analysis timeline compiling the 2023 FDA reclassification of ~17 peptides (BPC-157, TB-500, CJC-1295, etc.), the Dec 2024 warning-letter wave, and the 2025 GLP-1 shortage resolutions. An industry site (affiliate-adjacent), not independent journalism; publication date approximate.
Industry tracker/blog — not independently verifiedsource - Forum2025-06-18· Industry blogs/forums (Muscle & Brawn, Evolutionary.org)
Amino Asylum's Memphis warehouse raided by federal agents; site goes dark
Multiple industry sources report federal agents raided Amino Asylum's Memphis, TN warehouse around June 18, 2025, with the website going offline. Reported by forum/affiliate sources, not mainstream press, but the underlying conduct was later confirmed by owner Matthew Kawa's Dec 2025 DOJ guilty plea. Date is approximate.
Community/forum report — treat as unconfirmedsource - Official record2025-04-15· U.S. International Trade Commission / Federal Register
ITC issues General Exclusion Order on tirzepatide and knock-off 'tirzepatide' products
The ITC issued a General Exclusion Order directing U.S. Customs to block imports of knock-off tirzepatide products, after finding seven entities likely to deceive consumers about whether their imported 'tirzepatide' was genuine, FDA-approved, or contained the drug at all. Stemmed from an Eli Lilly complaint.
Primary government, court, or regulatory documentsource - Official record2025-02-21· U.S. Food & Drug Administration
FDA clarifies compounding policy as GLP-1 shortages resolve, setting enforcement deadlines
FDA declared the tirzepatide shortage resolved (Dec 19, 2024) and the semaglutide shortage resolved (Feb 21, 2025), ending the enforcement-discretion window that had let compounders mass-produce the drugs. This is the regulatory event that legally ended the compounded-GLP-1 boom.
Primary government, court, or regulatory documentsource FDA Warning Letter to SwissChems (MARCS-CMS 695663)
FDA cited SwissChems for marketing semaglutide and retatrutide as unapproved new drugs intended for human use, using the company's own product-page language as evidence. Issued the same day as letters to Summit Research Peptides, Prime Peptides and Xcel Peptides in a coordinated peptide/GLP-1 warning-letter wave.
Primary government, court, or regulatory documentsource- News2024-10-21· Reuters (via AOL)
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly filed a fresh round of lawsuits against online vendors and a medical spa selling compounded 'copycat' tirzepatide, alleging false advertising. By this point Lilly had already sued more than two dozen med spas, wellness centers and compounders.
Reported by an established news outletsource Eli Lilly names Paradigm Peptides as a respondent in ITC tirzepatide complaint
Eli Lilly's ITC complaint over imported knock-off tirzepatide named Paradigm Peptides of Michigan City, Indiana among the respondents, part of the investigation that led to the April 2025 General Exclusion Order.
Primary government, court, or regulatory documentsource